Crispr Therapeutics shares tumble after significant earnings miss
BofA Securities raised its price target on Fresenius Medical (TASE:BLWV) Care AG & Co KGaA (FME:GR) (NYSE:FMS) to €56.00 from €55.00 while maintaining a Neutral rating. The adjustment follows the company’s Capital Markets Day held in London on Tuesday.
During the event, Fresenius Medical Care management updated its medium-term targets, aiming for mid-teen EBIT margin by 2030, capital expenditure of €0.8-€1.0 billion, and reduced leverage of 2.5x-3.0x from the previous 3.0x-3.5x range. The company also announced a 30-40% dividend payout and a €1 billion share buyback program over two years, with potential renewal at its 2026 annual general meeting. These targets appear achievable given the company’s robust free cash flow yield of 13% and healthy current ratio of 1.46.
Fresenius Medical Care stock fell 5% following the announcements in what BofA described as a "sell the news" reaction. The research firm noted that expectations were high heading into the Capital Markets Day, with shares having gained approximately 30% from their April trough to May peak.
The 5008x dialysis machine roll-out was a key focus of the presentation. BofA indicated that investor questions would likely center on the absence of medium-term revenue targets following the event.
BofA Securities increased its fiscal year 2025 and 2026 earnings per share estimates by 7% and 16% respectively, reflecting the newly announced FME25+ €300 million savings program and the share buyback initiative. For deeper insights into Fresenius Medical Care’s valuation and growth prospects, including 7 additional ProTips and comprehensive financial analysis, visit InvestingPro to access the full Pro Research Report.
In other recent news, Fresenius Medical Care has made significant announcements affecting its financial outlook and operations. The company revealed a new mid-teens adjusted operating income margin target by 2030, with anticipated improvements across its business segments and projected U.S. treatment growth exceeding 2% annually. Additionally, Fresenius Medical Care has launched a €1.0 billion share buyback program and adjusted its leverage target, moves aimed at enhancing financial flexibility. Truist Securities maintained a Hold rating and a $30 price target, highlighting the rollout of the 5008x HVHDF system as a key growth driver and noting increased savings in the FME25+ program.
Bernstein SocGen Group raised its price target for Fresenius Medical Care to $31.50 from $26.00, citing progress in restructuring efforts under CEO Helen Giza. Bernstein noted these efforts have begun to improve operational performance, projecting consistent double-digit earnings growth for the next five years. Despite maintaining a Market Perform rating, Bernstein views the stock as a tactical buying opportunity, with the new price target suggesting a potential 15% upside. These developments underscore Fresenius Medical Care’s strategic focus on long-term growth and financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.